QUEST DIAGNOSTICS INC News
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
see moreQUEST DIAGNOSTICS INC Market News
13d
Quest Diagnostics Attracts Hedge Fund Interest Following Strong Haystack MRD Clinical Data
- Hedge funds ramped up Quest Diagnostics (DGX) holdings by over 300% as the company reported robust clinical performance from its Haystack MRD test.
27d
Quest Diagnostics Expands Lab Access via Apple Health App for U.S. Consumers
Quest Diagnostics now enables U.S. users to order lab tests directly through the Apple Health app via a $119 in-app purchase, broadening consumer access.
23 Sep at 17:40
Quest Diagnostics Faces Headwinds as CMS Proposes Up to 15% Lab Reimbursement Cuts
Quest Diagnostics (DGX) stock dips as CMS unveils proposed lab reimbursement cuts of up to 15%, weighing on shares and investor outlook.
09 Sep at 17:39
Quest Diagnostics to Offer FDA‑Cleared Roche pTau217 Alzheimer’s Test, Expanding DGX’s Advanced Diagnostics Portfolio
Quest Diagnostics (DGX) will begin offering Roche’s FDA‑cleared pTau217 blood test for Alzheimer’s pathology, augmenting its AD‑Detect® offerings.
26 Aug at 17:39
Quest Diagnostics Declares $0.86 Quarterly Dividend Despite Quiet August
Quest Diagnostics (NYSE: DGX) has declared a $0.86 per share quarterly dividend amid minimal fresh developments in the past week.
12 Aug at 17:40
Quest Diagnostics Highlights Growing Community Health Initiatives Amid Financial Landscape
Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, has recently been involved in several significant activities that may influence its stock performance.